Safety and efficacy of sargramostim (GM‐CSF) in the treatment of Alzheimer's disease

Safety and efficacy of sargramostim (GM‐CSF) in the treatment of Alzheimer's disease

Abstract Introduction Inflammatory markers have long been observed in the brain, cerebrospinal fluid (CSF), and plasma of Alzheimer's disease (AD) patients, suggesting that inflammation contributes to AD and might be a therapeutic target. However, non‐steroidal anti‐inflammatory drug trials in...

Full description

Bibliographic Details
Main Authors: Huntington Potter, Jonathan H. Woodcock, Timothy D. Boyd, Christina M. Coughlan, John R. O'Shaughnessy, Manuel T. Borges, Ashesh A. Thaker, Balaibail A. Raj, Katarzyna Adamszuk, David Scott, Vanesa Adame, Paige Anton, Heidi J. Chial, Helen Gray, Joseph Daniels, Michelle E. Stocker, Stefan H. Sillau
Format: Article
Language:English
Published: Wiley 2021-01-01
Series:Alzheimer’s & Dementia: Translational Research & Clinical Interventions
Subjects:
activities of daily living
Alzheimer's disease
amyloid
cytokine
glial fibrillary acidic protein
granulocyte‐macrophage colony‐stimulating factor
Online Access:https://doi.org/10.1002/trc2.12158

Internet

https://doi.org/10.1002/trc2.12158

Similar Items